Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Debt / NOTE 2.250% 3/0
-
Market price (% of par)
-
99.8%
-
Total 13F principal
-
$277,011,293
-
Principal change
-
+$12,948,430
-
Total reported market value
-
$276,983,110
-
Number of holders
-
28
-
Value change
-
+$13,928,963
-
Number of buys
-
17
-
Number of sells
-
15
Institutional Holders of TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 as of Q1 2025
As of 31 Mar 2025,
TRAVERE THERAPEUTICS INC - NOTE 2.250% 3/0 was held by
28 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$277,011,293
in principal (par value) of the bond.
The largest 10 bondholders included
Linden Advisors LP, D. E. Shaw & Co., Inc., Voya Investment Management LLC, Graham Capital Management, L.P., WOLVERINE ASSET MANAGEMENT LLC, Jump Financial, LLC, JANUS HENDERSON GROUP PLC, LORD, ABBETT & CO. LLC, Point72 Asset Management, L.P., and OAKTREE CAPITAL MANAGEMENT LP.
This page lists
28
institutional bondholders reporting positions
for the Q1 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.